One of the biggest businesses today is the business of contraceptives, with numerous women opting for permanent contraceptives rather than the old fashioned oral ones.
Birth control pills and injectable contraceptives are the highly common practice the women would do today. There is also another one, IUD.
Today though, with medical tech at its prime, implants are becoming highly sought by women.
Most implants boasts very low pregnancy risks, almost only one percent.
Bayer Sterility Device is now under fire after numerous women voiced out having allergic reactions from their contraceptive implants.
In a recent study women who have the Essure implants are 10 times more likely to have post-surgical operations done to them compared to women who had the standard sterility surgery.
The study also states that over 750,000 women have the Essure implants around the world, with 70 percent of them in America. The scope of the study is huge and could be inaccurate.
Researcher Weill Cornell said that the 10-fold high occurrence of reoperation during the first year following implantation of the Essure implants is a cause for concern despite only a number of women complaining.
The company then commented that the implants are highly-effective for women who wants permanent contraception with non-surgical operations. They also pointed out that decades of study with the implants assure it to be safe and effective.
Essure are implants that consist of two small nickel-titanium coils inserted through the vagina and cervix and into the fallopian tube of the women. The pathway of the sperm and egg are blocked through inflammation and fibrous tissue growth.
Food and Drugs Administration is in talks whether Essure should face restrictions or label changes. A panel of the FDA had a discussion last month to mull the benefits and risk of the Essure implants. The FDA promises to review the study involving the Essure implants and to put it as high priority issue.
